Education
About Us
Working with TipRanks
Follow Us
Quanterix Corporation (QTRX)
NASDAQ:QTRX
QTRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.05 - $15.67
Previous CloseN/A
Volume125.22K
Average Volume (3M)682.34K
Market Cap
$246.27M
Enterprise Value$33.00M
Total Cash (Recent Filing)$261.17M
Total Debt (Recent Filing)$35.53M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 05, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding46,465,916
10 Day Avg. Volume666,524
30 Day Avg. Volume682,341
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue0.26
Enterprise Value/Gross Profit0.47
Enterprise Value/Ebitda-0.39
Forecast
1Y Price Target
$6.30Price Target Upside18.87% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Demand TrendsManagement is seeing encouraging signs of future demand, including an increase in the total number of accelerator lab customers.
Pricing StrategyCMS released the clinical lab fee schedule's preliminary determinations, which crosswalked QTRX's LucentAD Complete test to a $897 price.
Product LaunchNew product launches and benefits from the Akoya acquisition should drive stronger performance and valuation levels higher for QTRX over time.
Bears Say
Competitive PositioningQTRX is starting to lag behind competitors, with Fujirebio's BBM already FDA approved, and QTRX does not expect FDA approval until 2026.
Growth ConcernsQTRX updated its revenue guidance to a lower range of $100M-$105M, raising concerns about future growth potential.
Revenue PerformanceTotal revenue of $24.5M fell short of already lowered expectations, with significant declines in both academic and pharma sectors.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $4.05 and its highest was $15.67 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $246.27M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Nov 05, 2025 which is in 40 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on Aug 07, 2025. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.422 by -$0.348.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.47.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 46,465,916 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.422. Following the earnings report the stock price went down -13.793%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
Quanterix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.30 (18.87% Upside)
$6.30 (18.87% Upside)
Hedge Fund Trend
Decreased
By 142.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $19.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.81%
12-Months-Change
Fundamentals
Return on Equity
-22.27%
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
QTRX Company Deck
QTRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of strategic achievements and significant challenges. The company highlighted strong strategic moves and synergies following the Akoya acquisition, a stable consumables revenue stream, and expansion into new market segments. However, these positives were overshadowed by considerable revenue declines, particularly in academic and pharma sales, alongside increased operating expenses and a significant drop in gross margin. The company's focus on long-term growth and cost savings offers a positive outlook, but current financial challenges are significant.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$6.30
▲(18.87% Upside)
Technical Analysis
Ownership Overview
7.32% Insiders
14.72% Mutual Funds
31.22% Other Institutional Investors
36.81% Public Companies and Individual Investors